prasugrel or ticagrelor or aspirin + clopidogrel

This entry refers to a set of dual antiplatelet therapy regimens used for the prevention of thrombotic cardiovascular events, especially in patients with acute coronary syndrome (ACS) and those undergoing percutaneous coronary intervention (PCI). The regimens include either prasugrel or ticagrelor as single agents (typically used in combination with aspirin), or the combination of aspirin plus clopidogrel. All three approaches act by inhibiting platelet aggregation but differ in their mechanisms and potency. Prasugrel and ticagrelor are both oral P2Y12 receptor antagonists that provide more potent and predictable platelet inhibition than clopidogrel; prasugrel is an irreversible thienopyridine prodrug, while ticagrelor is a reversible cyclopentyltriazolopyrimidine that does not require metabolic activation. Aspirin inhibits cyclooxygenase 1, reducing thromboxane A2 production, while clopidogrel irreversibly blocks the P2Y12 ADP receptor on platelets. These therapies are indicated primarily for ACS management but may also be used for secondary prevention after myocardial infarction or stroke[1][4][5][6][7][9].

Brand names

EffientBrilintaPlavixClopitab-ADeplatt AClopivas APClavix-ASClopilet ACeruvin APreva-ASPlagerine-A

Other names

ASA + clopidogrel